X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs DR. DATSONS LABS - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA DR. DATSONS LABS ASTRAZENECA PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 89.2 -10.9 - View Chart
P/BV x 19.7 0.2 12,110.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
DR. DATSONS LABS
Mar-14
ASTRAZENECA PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,278126 1,017.5%   
Low Rs88331 2,856.3%   
Sales per share (Unadj.) Rs228.4133.0 171.7%  
Earnings per share (Unadj.) Rs10.40.2 6,835.9%  
Cash flow per share (Unadj.) Rs16.36.6 246.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.8128.8 76.7%  
Shares outstanding (eoy) m25.0031.66 79.0%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.70.6 803.9%   
Avg P/E ratio x104.2516.1 20.2%  
P/CF ratio (eoy) x66.411.8 561.0%  
Price / Book Value ratio x10.90.6 1,800.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0082,477 1,090.2%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,53556 2,741.6%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,7104,211 135.6%  
Other income Rs m12379 155.7%   
Total revenues Rs m5,8334,289 136.0%   
Gross profit Rs m463569 81.4%  
Depreciation Rs m147204 72.1%   
Interest Rs m0430 0.0%   
Profit before tax Rs m43813 3,448.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1796 2,932.8%   
Profit after tax Rs m2595 5,397.9%  
Gross profit margin %8.113.5 60.0%  
Effective tax rate %40.848.0 85.0%   
Net profit margin %4.50.1 3,980.4%  
BALANCE SHEET DATA
Current assets Rs m3,2096,852 46.8%   
Current liabilities Rs m2,0706,711 30.8%   
Net working cap to sales %20.03.3 596.0%  
Current ratio x1.61.0 151.9%  
Inventory Days Days72161 45.0%  
Debtors Days Days35318 11.0%  
Net fixed assets Rs m7903,673 21.5%   
Share capital Rs m50317 15.8%   
"Free" reserves Rs m2,4193,761 64.3%   
Net worth Rs m2,4694,078 60.6%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m4,60512,633 36.5%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.3 372.0%   
Return on assets %5.63.4 163.4%  
Return on equity %10.50.1 8,913.5%  
Return on capital %17.77.7 231.2%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m300964 31.1%   
Fx outflow Rs m2,015607 331.9%   
Net fx Rs m-1,715357 -480.6%   
CASH FLOW
From Operations Rs m881,345 6.5%  
From Investments Rs m-94-2,256 4.1%  
From Financial Activity Rs mNA-1,200 0.0%  
Net Cashflow Rs m-6-2,111 0.3%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 1.4 1,163.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 94.1 9.7%  
Shareholders   12,856 20,807 61.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS